Neuronex Inc.
http://www.neuronexinc.com/index.html
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Latest From Neuronex Inc.
VC Roundup: Three New Funds Close As Small, Early Financings Bounce Back
Even Series A rounds have been large during recent record-breaking years for biotech venture capital investment, but it looks like smaller financings for early-stage companies may be in the midst of a comeback. With VC firms closing new funds, that raises the question: Will the number of preclinical and Phase I financings increase?
Acorda Drops Epilepsy Candidate Once Central To Its Revenue Forecasts
Plumiaz, a nasal spray formulation of diazepam, is discontinued after it fails one of three Phase III trials undertaken to comply with 2014 FDA complete response letter.
Acorda Drops Epilepsy Candidate Once Central To Its Revenue Forecasts
Plumiaz, a nasal spray formulation of diazepam, is discontinued after it fails one of three Phase III trials undertaken to comply with 2014 FDA complete response letter.
New Anti-Epileptic Drug Formulations Try To Overcome Tolerability Problems
Much of the drug development activity in epilepsy is focused on improving the existing treatments.
Company Information
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Email Company
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice